Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Surgery Remains Vital in Hepatobiliary Neoplasms

Angelica Welch
Published: Friday, Jun 08, 2018

Theodore H. Welling, MD

Theodore H. Welling, MD

The role of surgery across a variety of tumor types seems to be changing with the success of targeted therapies and immune-oncology agents. However, in hepatobiliary neoplasms, surgery remains a mainstay of treatment.

As new agents are introduced into the treatment landscape of hepatobiliary neoplasms, the role of surgery continues to grow in hepatocellular carcinoma (HCC) and cholangiocarcinoma, says Theodore H. Welling, MD. Moreover, locoregional therapies and chemotherapy have been shown to downstage patients with these malignancies, which allows for a greater number of individuals to be eligible for surgery.

“Surgery will have an increasing role, because we will be able to bring in more patients for definitive therapy,” says Welling. “There certainly have been some cases where we have seen a complete response, and we are certainly hopeful that there will be more of those cases. Overall, if we take things in totality, it’s going to offer more options for more patients.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication